bioAffinity Technologies, Inc.
BIAF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,446 | $1,269 | $1,854 | $2,208 |
| % Growth | 13.9% | -31.5% | -16% | – |
| Cost of Goods Sold | $1,056 | $1,017 | $1,368 | $1,716 |
| Gross Profit | $390 | $253 | $486 | $492 |
| % Margin | 27% | 19.9% | 26.2% | 22.3% |
| R&D Expenses | $474 | $441 | $506 | $518 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,209 | $2,215 | $2,453 | $2,920 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $113 | $155 | $0 |
| Operating Expenses | $2,683 | $2,768 | $3,113 | $3,438 |
| Operating Income | -$2,293 | -$2,516 | -$2,627 | -$2,947 |
| % Margin | -158.6% | -198.2% | -141.7% | -133.5% |
| Other Income/Exp. Net | -$2,755 | -$1,516 | -$25 | -$20 |
| Pre-Tax Income | -$5,048 | -$4,032 | -$2,652 | -$2,967 |
| Tax Expense | $3 | $29 | $9 | $0 |
| Net Income | -$5,051 | -$4,061 | -$2,660 | -$2,967 |
| % Margin | -349.3% | -319.9% | -143.5% | -134.4% |
| EPS | -4.74 | -5.07 | -4.8 | -6.3 |
| % Growth | 6.5% | -5.6% | 23.8% | – |
| EPS Diluted | -4.74 | -5.07 | -4.8 | -6 |
| Weighted Avg Shares Out | 1,066 | 801 | 542 | 413 |
| Weighted Avg Shares Out Dil | 1,066 | 801 | 542 | 413 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $1 | $4 |
| Interest Expense | $5 | $10 | $15 | $25 |
| Depreciation & Amortization | $113 | $113 | $155 | $154 |
| EBITDA | -$4,929 | -$3,908 | -$2,482 | -$2,788 |
| % Margin | -340.9% | -307.9% | -133.9% | -126.3% |